assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with b-cell malignancies
Published 2 months ago • 142 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
1:06
zanubrutinib in patients with b-cell malignancies who are acalabrutinib-intolerant
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
2:06
identification of genetic markers associated with ibrutinib-related cardiovascular toxicity
-
1:11
long-term safety analysis of pirtobrutinib in r/r b-cell malignancies
-
1:09
ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
-
1:07
characterizing distinct mechanisms of heart failure in patients with sickle cell disease
-
11:55
updates in cll from eha 2024: combinations of btk and bcl2 inhibitors, btk degraders, and more
-
46:18
eha 2024 - updates on cll with dr. banerji, dr. assouline, and dr. hillis
-
29:21
haemostasis overview
-
1:29
insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
2:13
current and emerging treatment options for patients with mf who are ineligible for ruxolitinib
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:29
bellwave-011: nemtabrutinib vs ibrutinib/acalabrutinib in treatment-naïve cll/sll
-
3:56
results of the phase ii titan study of caplacizumab in patients with attp
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma